Assess
Baseline cognitive and symptom profiling pinpoints each patient's specific deficits and starting point.
The science behind the game
Depression isn't only low mood — it has measurable cognitive roots. Meliora is built to reach them, grounded in roughly a decade of neuroscience research.
The mechanism
Assess. Adapt. Treat.
Adapt
An adaptive engine recalibrates difficulty in real time, keeping training in the zone that drives neural change.
Treat
Sustained, targeted engagement aims to reduce depressive symptoms by exercising fronto-parietal cognitive control.
Meliora targets the cognitive deficits and fronto-parietal hypoactivity associated with depression — a mechanism that antidepressants and psychotherapy do not directly address.
The scale of the problem
Why this matters
0
People living with depression globally
0
Estimated treatment-resistant share
0
Of neuroscience research behind Meliora
0
Founded · Aalto University spin-out
Prevalence and treatment-resistance figures are approximate and illustrative of the global burden of disease; see notes below.
Clinical program
Trial design at a glance
An overview of how Meliora is being evaluated. Details below are illustrative of the program and will be confirmed through the clinical and regulatory process.
| Parameter | Detail |
|---|---|
| Indication | Major depressive disorder (adults) |
| Design | Randomized, controlled evaluation |
| Intervention | Meliora — adaptive cognitive training + narrative |
| Primary endpoint | Change in depressive symptom score from baseline |
| Key comparator | Standard of care / control |
| Status | Investigational — not yet cleared by regulators |
Early results have shown significant symptom reduction comparable to psychotherapy, but faster. Figures and design parameters are illustrative pending peer-reviewed publication.
“A treatment that reaches the cognitive roots of depression — delivered through something people want to play.”
Clinical questions
The evidence, explained
The fronto-parietal network supports attention and cognitive control. In depression it is often underactive, contributing to difficulties with concentration and executive function. Meliora's adaptive training is designed to engage and exercise this network.
The clinically active ingredient is the adaptive cognitive training; the narrative drives the adherence needed to deliver a meaningful therapeutic dose. Together they aim to produce measurable, sustained symptom reduction.
Meliora targets cognitive symptoms those treatments don't directly address, and is intended to complement rather than replace them. Early results indicate symptom reduction comparable to psychotherapy, but faster. These findings are investigational and pending publication.
Our clinical program is ongoing and figures on this page are illustrative pending peer-reviewed publication and regulatory review. For research collaboration or data requests, please contact us.
References & notes
A note on the numbers
Global prevalence (~280M people) and treatment-resistance estimates (~30%) reflect widely cited public-health figures for depression and are presented to illustrate the scale of the problem, not as outputs of our program.
Statements about Meliora's mechanism and early results describe internal and program-stage findings that are investigational and pending peer-reviewed publication and regulatory review. Nothing on this page constitutes medical advice.
Investigational — not yet cleared by regulators.
Explore the product
See how the science comes together inside Meliora — or reach out about clinical and research collaboration.